These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38172306)

  • 1. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.
    Li XX; Chen ZD; Sun XJ; Yang YQ; Jin H; Liu NF
    Acta Pharmacol Sin; 2024 Apr; 45(4):751-764. PubMed ID: 38172306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies.
    Liu P; Zhang Z; Wang J; Zhang X; Yu X; Li Y
    Bioengineered; 2021 Dec; 12(2):9356-9366. PubMed ID: 34823419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable effect of rivaroxaban against vascular dysfunction in diabetic mice by inhibiting NLRP3 inflammasome activation.
    Li Q; Yang XT; Wei W; Hu XP; Li XX; Xu M
    J Cell Physiol; 2022 Aug; 237(8):3369-3380. PubMed ID: 35675485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome.
    Chen A; Lan Z; Li L; Xie L; Liu X; Yang X; Wang S; Liang Q; Dong Q; Feng L; Li Y; Ye Y; Fu M; Lu L; Yan J
    Cardiovasc Res; 2023 Oct; 119(13):2368-2381. PubMed ID: 37523743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of acarbose against vascular endothelial dysfunction through inhibiting Nox4/NLRP3 inflammasome pathway in diabetic rats.
    Li XX; Ling SK; Hu MY; Ma Y; Li Y; Huang PL
    Free Radic Biol Med; 2019 Dec; 145():175-186. PubMed ID: 31541678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salidroside alleviates diabetic neuropathic pain through regulation of the AMPK-NLRP3 inflammasome axis.
    Zheng T; Wang Q; Bian F; Zhao Y; Ma W; Zhang Y; Lu W; Lei P; Zhang L; Hao X; Chen L
    Toxicol Appl Pharmacol; 2021 Apr; 416():115468. PubMed ID: 33639149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
    Gordon M; Meagher P; Connelly KA
    Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice.
    Yu Y; Chen D; Zhao Y; Zhu J; Dong X
    Int J Immunopathol Pharmacol; 2021; 35():20587384211036819. PubMed ID: 34399601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
    Gong Q; Zhang R; Wei F; Fang J; Zhang J; Sun J; Sun Q; Wang H
    Biomed Pharmacother; 2022 Aug; 152():113222. PubMed ID: 35671581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Empagliflozin on Vascular and Skeletal Mineralization in Hyperlipidemic Mice.
    Kalanski S; Pradhan S; Hon A; Xia Y; Safvati N; Rivera JC; Lu M; Demer LL; Tintut Y
    Vascul Pharmacol; 2024 Jun; 155():107376. PubMed ID: 38692418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of redox-dependent activation of endothelial Nlrp3 inflammasomes to hyperglycemia-induced endothelial dysfunction.
    Chen Y; Wang L; Pitzer AL; Li X; Li PL; Zhang Y
    J Mol Med (Berl); 2016 Dec; 94(12):1335-1347. PubMed ID: 27783111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.
    Ye T; Zhang J; Wu D; Shi J; Kuang Z; Ma Y; Xu Q; Chen B; Kan C; Sun X; Han F
    Front Endocrinol (Lausanne); 2022; 13():907984. PubMed ID: 35784553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
    Byrne NJ; Matsumura N; Maayah ZH; Ferdaoussi M; Takahara S; Darwesh AM; Levasseur JL; Jahng JWS; Vos D; Parajuli N; El-Kadi AOS; Braam B; Young ME; Verma S; Light PE; Sweeney G; Seubert JM; Dyck JRB
    Circ Heart Fail; 2020 Jan; 13(1):e006277. PubMed ID: 31957470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paeoniflorin ameliorates diabetic liver injury by targeting the TXNIP-mediated NLRP3 inflammasome in db/db mice.
    Wang A; Gong Y; Pei Z; Jiang L; Xia L; Wu Y
    Int Immunopharmacol; 2022 Aug; 109():108792. PubMed ID: 35483236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrodin Alleviates Cognitive Dysfunction and Depressive-Like Behaviors by Inhibiting ER Stress and NLRP3 Inflammasome Activation in db/db Mice.
    Ye T; Meng X; Wang R; Zhang C; He S; Sun G; Sun X
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.